

Plenary Session 2: Landscape

Measles Aerosol Vaccine

Measles Vaccine, Dry Powder (Inhalable)

Next-Generation Vaccine Delivery Technology Meeting

Geneva, Switzerland

Name: Dr.S.S.Jadhav

Email: ssj@seruminstitute.com


Title: Executive Director SSI

Date: February 18, 2014

CAN-BD Spray Drying System



Technology Description:

- Carbon Dioxide Assisted Nebulization with a Bubble Dryer®



Measles Vaccine, Dry Powder (Inhalable)

PuffHaler



Solovent™ devices





ADAPTIVE SPACER DESIGN
FOR ADULTS & CHILDREN -
CONFIGURED AT TIME OF USE

Measles Vaccine, Dry Powder (Inhalable)

Status:

- ✓ Validation
- ✓ Technology transfer
- ✓ Bench testing
- ✓ Animal immunogenicity
- ✓ Animal Toxicity
- ✓ Phase 1 in healthy adults



Measles Vaccine, Dry Powder (Inhalable)

Benefits:

- ✓ Non injectable, easier to administer
- ✓ No waste disposal
- ✓ Competitive cost per dose

Challenges:

- Need data from Phase II and III clinical trials to further assess immunogenicity and safety
- Resources to complete clinical development
- Scale up of manufacturing



Measles Vaccine, Dry Powder: Opportunities and Way Forward

Global Public Health Challenge:

- Simplify delivery of vaccine
- Reduce safety concerns
- Expand coverage

Technology Availability:

- <Probability of technology availability for program use in the next 10 – 20 years if not sooner>
- <What is needed to realize availability of technology?>
- <Suggestions for the way forward>



[http://www.aktiv-dry.com/
images/
Aktiv_Dry_for_Powerpoint.m
ov](http://www.aktiv-dry.com/images/Aktiv_Dry_for_Powerpoint.mov)